Status:
COMPLETED
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
Lead Sponsor:
Ever Neuro Pharma GmbH
Collaborating Sponsors:
IDV Data analysis and study planning Dr. Rahlfs
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18+ years
Brief Summary
This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.
Detailed Description
Patients registered: Acute Ischemic Stroke patients with moderate to severe neurological deficits All patients receive acute stroke care according to local treatment standards, not amended or influen...
Eligibility Criteria
Inclusion
- Signed Informed Consent
- Clinical diagnosis of acute ischemic stroke confirmed by imaging
- Moderate to severe neurological deficits with NIH Stroke Scale (NIHSS) 8 to 15, both inclusive
- No prior stroke
- No prior disability
- Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)
- Reasonable expectation of successful follow-up (max. 100 days)
Exclusion
- none
Key Trial Info
Start Date :
April 24 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2024
Estimated Enrollment :
1851 Patients enrolled
Trial Details
Trial ID
NCT03480698
Start Date
April 24 2018
End Date
July 15 2024
Last Update
February 25 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Landesklinikum Amstetten
Amstetten, Austria, 3300
2
Krankenhaus der Barmherzigen Brüder Eisenstadt
Eisenstadt, Austria, 7000
3
Universitätsklinik Innsbruck
Innsbruck, Austria, 6020
4
Kepler Universitätsklinikum
Linz, Austria, 4021